Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 12, Issue 3, Pages 612-622Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2015.1105415
Keywords
cellular immunity; Dendritic cells; humoral immunity; target; vaccine
Categories
Funding
- Chinese 863 National Programs for High Technology Research and Development [2011AA10A211]
- National Pig Industrial System [CARS-36-06B]
- Special Fund for Agro-scientific Research in the Public Interest [201203039]
Ask authors/readers for more resources
Dendritic cells (DCs) are known to be a set of morphology, structure and function of heterogeneous professional antigen presenting cells (APCs), as well as the strongest functional antigen presenting cells, which can absorb, process and present antigens. As the key regulators of innate and adaptive immune responses, DCs are at the center of the immune system and capable of interacting with both B cells and T cells, thereby manipulating the humoral and cellular immune responses. DCs provide an essential link between the innate and adaptive immunity, and the strong immune activation function of DCs and their properties of natural adjuvants, make them a valuable target for antigen delivery. Targeting antigens to DC-specific endocytic receptors in combination with the relevant antibodies or ligands along with immunostimulatory adjuvants has been recently recognized as a promising strategy for designing an effective vaccine that elicits a strong and durable T cell response against intracellular pathogens and cancer. This opinion article provides a brief summary of the rationales, superiorities and challenges of existing DC-targeting approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available